Centre of Top Expertise in Northern Europe

BioTurku® is the leading biotechnology cluster in Finland, an active and dynamic community of bio actors and a centre of top expertise in Northern Europe. Approx. half of Finland's pharmaceutical and diagnostics industry is located in the Turku region in southwest Finland.

The BioTurku cluster comprises about 90 biotechnology companies, two universities and several educational and research institutes as well as the Turku University Hospital. It forms a continuous chain of education, research, product development, production and commercialization. BioTurku is part of Turku Science Park, one of Finland's oldest and largest science parks.

Diagnostics in BioTurku®

The diagnostics research and business community in BioTurku comprises research and development of new biomarkers and biosensors, as well as development of new technologies for diagnosis and bioimaging.  Point-of-care (POC) concept has been a leading goal in the development of new assays to gain benefit for patients and for society.

As a result there are already traditional and advanced IVD technologies in applications for diagnosis of human diseases, monitoring of food safety and quality, household and pet animal testing, agriculture and environmental monitoring and bio-technological industries.

The Turku biobanking concept is a global advantage in the research for new biomarkers aimed at human disease areas such as cancer, cardiovascular diseases, diabetes, infection and central nervous system; food contaminants and toxic residues as well as environmental chemicals and pathogens.

New innovative detection and automation technologies are also developed in several laboratories to

  • detect interaction at molecular level
  • characterize relevant biomarkers in target diseases
  • develop more sensitive reagents and tracers with low background, high thermodynamic stability and long signal lifetime in immunology, nucleic acid and PET techniques
  • develop new lanthanide chelates for bioassays on TR-FIA and TR-FRET
  • develop new detection methods like electrochemiluminescence
  • develop new assays with nucleic acid technology

New biomedical instrumentation is developed and manufactured with new detection and automation technologies for in vitro diagnosis, imaging at atomic force level and fluidistic systems.

New material science and microelectronics give advanced possibilities in the development of new biosensors.

Examples of Companies to Visit

  • Hidex

    Hidex Oy is a family owned high technology company which develops and manufactures high performance analysis equipment for life science research, nuclear measurement and nuclear medicine markets. With our global distribution network our instruments are being sold all over the world. Hidex products are used to: 

    • Study new innovations in medicine and biology. 
    • Guarantee the safety of food and drinking water and
    • Advance the safety and efficiency of nuclear industry.

    Hidex has vast experience in the development of high performance analytical equipment and our manufacturing is based in Finland. Our products utilize modern technology and excellent tradition of workmanship. With strong links to the scientific community we continue to innovate and develop to improve scientific research and safety of everyday life.

  • Labrox

    Labrox Ltd develops and manufactures plate readers. Founded in 2011, its owners have a combined experience of more than 90 years in developing world leading plate readers. Labrox has developed an innovative microplate reader platform. With this platform we can tailor instruments according to the current needs of the customer. We have hands-on experience about almost all plate reader measurement technologies and are able to combine all the needed measurement technologies to a one compact laboratory instrument or we can do dedicated cost-efficient instruments with only one measurement technology. Instrument types can vary from high-throughput screening (HTS) instruments to small and portable instruments to be used in the field or near the patient as point-of-care (POC) instruments.

  • ArcDia International

    ArcDia International Oy Ltd is a company for R&D, manufacturing and marketing of innovative products for point-of-care testing of acute infectious diseases. 

    ArcDia has developed an automated continuous-feed immunoassay system for rapid near-patient testing of infectious diseases. ArcDia's first product was launched in the European market in 2010 under the trademark of mariPOC®.

    mariPOC® is the first product on the market to enable rapid multianalyte testing of respiratory pathogens at the point-of-care setting. The test panel covers viruses and bacteria for most common respiratory infections, including influenza type illnesses and tonsillitis. mariPOC® test panel recognized also pandemic influenza strains, such as swine (H1N1v) and avian (H5N1) influenzas. Tests for other infectious diseases are on the pipe-line.

  • Modern Diagnostics

    Modern Diagnostics Ltd. provides most advanced Next Generation Sequencing service and highest expertise service for clinicians dealing with the most serious diseases of small children. We offer high-tech solution for the genetic diagnosis of vast majority of fatal hereditary diseases in a single test. Our main product is LifeGuard™ Gene Panel that is designed to diagnose all serious neonatal conditions that may be fatal to the baby and are otherwise difficult to diagnose by a paediatrician or obstetrician. These diseases may be treatable and sometimes life of the baby can be saved. These include arrythmias, respiratory insufficiency, sleep apnea syndrome (Ondine’s Curse), fatty-acid oxidation disorders, and many others. Please welcome to see our comprehensive gene panel and details in our web pages!